

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number
WO 03/015771 A1

(51) International Patent Classification⁷: **A61K 31/42**,
C07D 261/08

(21) International Application Number: PCT/US02/25437

(22) International Filing Date: 13 August 2002 (13.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01119473.5 13 August 2001 (13.08.2001) EP
10/185,721 1 July 2002 (01.07.2002) US

(71) Applicant (*for all designated States except US*): **LION BIOSCIENCE AG** [DE/DE]; Waldhofer Strasse 98, D-69123 Heidelberg (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BAUER, Ulrike** [—/DE]; Wingerstr. 24, D-69207 Sandhausen (DE). **CHERUVALLATH, Zach** [—/US]; 7813 Roan Road, San Diego, CA 92129 (US). **DEUSCHLE, Ulrich** [—/DE]; Lilienstr. 19, D-69245 Bammental (DE). **DNEPROVSKAIA, Elena** [—/US]; 4080 Huerfano Avenue, #351, San Diego, CA 92117 (US). **GAHMAN, Tim** [—/US]; 262 Chapalita, Encinitas, CA 92024 (US). **GIEGRICH, Kristina** [—/DE]; Firnheimerstr. 32, D-68623 Lampertheim (DE). **HANECAR, Ronnie** [—/US]; 904 Calle Venezia, San Clemente, CA 92672 (US). **HEBERT, Normand** [—/US]; 1861 Montgomery Avenue, Cardiff, CA 92007 (US). **KIELY, John** [—/US]; 4230 Corte Facil, San Diego, CA 92130 (US). **KOBER, Ingo** [—/US]; Am Grossen Wald 30, D-69251 Gaiberg (DE). **KOGL, Manfred** [—/DE]; Hauptstr. 131/4, D-69214 Eppelheim (DE). **KRANZ, Harald** [—/DE]; Barenpfad 9, D-69181 Leimen (DE). **KREMOSER,**

Claus [—/DE]; Mozartstr. 29, D-69121 Heidelberg (DE). **LEE, Matthew** [—/US]; 1544 Santa Elena Court, Solana Beach, CA 92075 (US). **OTTE, Kerstin** [—/DE]; Biethstr. 20, D-69121 Heidelberg (DE). **SAGE, Carlton** [—/US]; 1232 Greenlake Drive, Cardiff, CA 92007 (US). **SUD, Manish** [—/US]; 4411 Cather Avenue, San Diego, CA 92122 (US).

(74) Agents: **TOFFENETI, Judith, L.** et al.; McDermott, Will & Emery, 600 13th Street, N.W., Washington, DC 20005 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS**

(57) Abstract: The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists, antagonists or mixed agonists / antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.

BEST AVAILABLE COPY



WO 03/015771 A1

FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS

Field of the Invention

[001] The present invention relates to compounds according to the general formulae (1), (2), (3) and (4) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists / antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

Background of the Invention

[002] Multicellular organisms are dependent on advanced mechanisms of information transfer between cells and body compartments. The information that is transmitted can be highly complex and can result in the alteration of genetic programs involved in cellular differentiation, proliferation, or reproduction. The signals, or hormones, are often simple molecules, such as peptides, fatty acid, or cholesterol derivatives.

[003] Many of these signals produce their effects by ultimately changing the transcription of specific genes. One well-studied group of proteins that mediate a cell's response to a variety of signals is the family of transcription factors known as nuclear receptors, hereinafter referred to often as "NR". Members of this group include receptors for steroid hormones, vitamin D, ecdysone, cis and trans retinoic acid, thyroid hormone, bile acids, cholesterol-derivatives, fatty acids (and other peroxisomal proliferators), as well as so-called orphan receptors, proteins that are structurally similar to other members of this group, but for which no ligands are known (Escriva, H. et al., Ligand binding was acquired during evolution of nuclear receptors, PNAS, 94, 6803 – 6808, 1997). Orphan receptors may be indicative of unknown signaling pathways in the cell or may be nuclear receptors that function without ligand activation. The activation of transcription by some of these orphan receptors may occur in the

absence of an exogenous ligand and/or through signal transduction pathways originating from the cell surface (Mangelsdorf, D. J. et al., *The nuclear receptor superfamily: the second decade*, Cell 83, 835-839, 1995).

[004] In general, three functional domains have been defined in NRs. An amino terminal domain is believed to have some regulatory function. A DNA-binding domain hereinafter referred to as "DBD" usually comprises two zinc finger elements and recognizes a specific Hormone Responsive Element hereinafter referred to as "HRE" within the promoters of responsive genes. Specific amino acid residues in the "DBD" have been shown to confer DNA sequence binding specificity (Schena, M. & Yamamoto, K.R., *Mammalian Glucocorticoid Receptor Derivatives Enhance Transcription in Yeast*, Science, 241:965-967, 1988). A Ligand-binding-domain hereinafter referred to as "LBD" is at the carboxy-terminal region of known NRs. In the absence of hormone, the LBD of some but not all NRs appears to interfere with the interaction of the DBD with its HRE. Hormone binding seems to result in a conformational change in the NR and thus opens this interference (Brzozowski et al., *Molecular basis of agonism and antagonism in the oestrogen receptor*, Nature, 389, 753 – 758, 1997; Wagner et al., *A structural role for hormone in the thyroid hormone receptor*, Nature, 378, 690 – 697, 1995). A NR without the HBD constitutively activates transcription but at a low level.

[005] Coactivators or transcriptional activators are proposed to bridge between sequence specific transcription factors and the basal transcription machinery and in addition to influence the chromatin structure of a target cell. Several proteins like SRC-1, ACTR, and Grip1 interact with NRs in a ligand enhanced manner (Heery et al., *A signature motif in transcriptional coactivators mediates binding to nuclear receptors*, Nature, 387, 733 – 736; Heinzel et al., *A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression*, Nature 387, 43 – 47, 1997). Furthermore, the physical interaction with repressing receptor-interacting proteins or corepressors has been demonstrated (Xu et al., *Coactivator and Corepressor complexes in nuclear receptor function*, Curr Opin Genet Dev, 9 (2), 140 – 147, 1999).

[006] Nuclear receptor modulators like steroid hormones affect the growth and function of specific cells by binding to intracellular receptors and forming nuclear receptor-ligand

complexes. Nuclear receptor-hormone complexes then interact with a hormone response element (HRE) in the control region of specific genes and alter specific gene expression.

[007] The Farnesoid X Receptor alpha (FXR; hereinafter also often referred to as NR1H4 when referring to the human receptor) is a prototypical type 2 nuclear receptor which activates genes upon binding to promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor (hereinafter RXR, Forman et al., Cell, 81, 687-93, 1995). The relevant physiological ligands of NR1H4 seem to be bile acids (Makishima et al., Science, 284, 1362-65, 1999; Parks et al., Science, 284, 1365-68, 1999). The most potent is chenodeoxycholic acid, which regulates the expression of several genes that participate in bile acid homeostasis.

[008] Farnesol, originally described to activate the rat ortholog at high concentration does not activate the human or mouse receptor. FXR is expressed in the liver, small intestine, colon, ovary, adrenal gland and kidney. Like LXR- α , NR1H4 is involved in autocrine signaling.

[009] FXR is proposed to be a nuclear bile acid sensor. As a result, it modulates both, the synthetic output of bile acids from the liver and their recycling in the intestine (by regulating bile acid binding protein). Upon activation (e.g. binding of chenodeoxycholic acid) it influences the conversion of dietary cholesterol into bile acids by inhibiting the transcription of key genes which are involved in bile acid synthesis such as CYP7A1 or in bile acid transport across the hepatocyte membranes such as the bile acid transporters BSEP (=Bile Salt Export Pump) and NTCP (Na-Taurocholate Co-Transporter). This seems to be a major mechanism of feedback regulation onto bile acid synthesis. Moreover, NR1H4 seems to be the crucial receptor for maintaining bile acid homeostasis within the hepatocyte and therefore might be an appropriate drug target to treat diseases that result from impaired bile acid production, impaired export into the bile canaliculi or impaired bile flow in general such as cholestatic conditions. Loss of function of NR1H4 results in major changes in bile acid homeostasis on the organism level (Lu, et al., Mol Cell. (2000) 6(3):507-15; Goodwin, et al., Mol Cell. (2000) 6(3):517-26; Sinal, et al., Cell (2000) 15;102(6):731-44).

[010] The synthetic compounds, 1,1-bisphosphonate esters, appear to display a number of similar activities to the two identified prototypes of natural FXR agonists, farnesol, and chenodeoxycholic acid. Like farnesol, the 1,1- bisphosphonate esters increase the rate of 3-

Hydroxy-3-methylglutaryl-CoA (HMG-CoA) Reductase degradation and like bile acids they induce the expression of the Intestinal Bile Acid Binding Protein (I-BABP) and repress the cholesterol 7 α -hydroxylase gene. Certain 1,1-bisphosphonate esters also bind to FXR. (Niesor et al., Curr Pharm Des, 7(4):231-59, 2001).. That means that activation of FXR could lead to opposing effects (lowering the rate of cholesterol synthesis by increasing degradation of HMG-CoA Reductase and increasing the cholesterol pool by inhibition of cholesterol degradation into bile acids). The FXR agonist chenodeoxycholic acid does not change cholesterol and lipoprotein levels significantly in patients, although a repression of bile acid synthesis as well as a decreased HMG-CoA Reductase activity was observed (Einarsson et al., Hepatology, 33(5), 1189-93, 2001) confirming that cellular cholesterol synthesis and degradation are controlled by numerous regulatory loops including the coordinate regulation of HMGCoA reductase and cholesterol 7 α -hydroxylase and that compounds modulating FXR activity might have different effects on blood lipid parameters.

[011] In the course of functional analysis of certain 1,1-bisphosphonate esters, it was shown that these compounds, which are known to bind to FXR also induce apoptosis in a variety of cell types, similar to the isoprenoids farnesol and geranylgeraniol, which are also known as weak FXR binders (Flach et al., Biochem Biophys Res Com, 270, 240-46, 2000).

[012] To date only very few compounds have been described which bind the NR1H4 receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor (Maloney et al., J Med Chem, 43(16):2971-4, 2000).

[013] It is currently believed that FXR agonists might be useful to treat cholestatic conditions because they result in an upregulation of bile acid transport activity across the canalicular hepatocyte membrane (Plass, et al., Hepatology. (2002) 35(3):589-96; Willson, et al., Med Res Rev. (2001) 21(6):513-22) . In contrast, it is believed that compounds that act as FXR antagonists or at least as mixed agonists / antagonists might reduce total serum cholesterol (Urizar, et al., Science (2002) 31;296(5573):1703-6).

[014] It was thus an object of the present invention to provide for novel NR1H4 binding compounds. It was thus an object of the present invention to provide for compounds which by means of binding the NR1H4 receptor act as agonist or antagonist or mixed agonist / antagonist

of said receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor.

[015] It was further an object of the invention to provide for compounds which may be used for the manufacture of a medicament for the treatment of cholesterol or bile acid associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for cholesterol lowering or anti-cholestatic compounds. It was also an object of the invention to provide for compounds that may be used for the manufacture of anticancer medicaments or apoptosis-inducing medicaments in general.

[016] It was further an object of the invention to provide for compounds which are orally available and can be used for an oral treatment of the diseases mentioned afore.

[017] The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

Brief Description of the Drawings

[018] Figure 1 shows the synthesis of the compounds according to the invention and as described in Example 2.


[019] Figure 2A is the amino acid sequence of the FXR protein, a portion of which was used for cloning as described in the examples (SEQ ID NO. 1). Figure 2B shows the nucleotide sequence (SEQ ID NO. 2) of FXR mRNA. Figure 2C is the amino acid sequence of TIF2 (ACC. NO: XM_011633 REFSEQ DB)(SEQ ID NO.3) and Figure 2D shows the nucleotide sequence of TIF2 mRNA (SEQ ID NO. 4).

[020] Figure 3 shows a dose-dependent transactivation ($EC_{50} \sim 1 \mu M$) of the reporter gene, luciferase, by FXR upon administration of different concentrations of compounds. Compounds LN169 and LN6734 that are within the scope of this patent application demonstrate a much higher potency in this assay than the published compound GW4064 or the natural ligand CDCA.

[021] Figure 4 shows a table with the underlying data to Fig 3.

Detailed Description of the Invention

[022] The invention provides for a compound including resolved diastereoisomers and enantiomers and tautomers, pharmaceutical acceptable salts or solvates thereof (hereinafter also referred to as the "compounds according to the invention"), having the following formula (I):



wherein,

[023] R_1 is hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, naphthyl or substituted naphthyl;

[024] R_2 is hydrogen C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, naphthyl or substituted naphthyl;

[025] R_3 is absent or if present selected from hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, phenyl, C_5 to C_8 heteroaryl, C_5 to C_8 substituted heteroaryl, substituted phenyl, biphenyl, substituted biphenyl, biphenyl ether, substituted biphenyl ether, biphenyl amine, substituted biphenyl amine, naphthyl and substituted naphthyl; and

[026] R_4 is absent, or if present, selected from hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, phenyl,

substituted phenyl, C₅ to C₈ heteroaryl, C₅ to C₈ substituted heteroaryl, biphenyl, substituted biphenyl, biphenyl ether, substituted biphenyl ether, biphenyl amine, substituted biphenyl amine, naphthyl and substituted naphthyl; M is O or N or S, however, when M is O or S, one of R₃ or R₄ must be absent; and





[027] X and Y are both hydrogen or both methyl or together represent a carbonyl group;

[028] R₃ and R₄ may be taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl ring.

[029] In one embodiment of the present invention R₁ and R₂ in formula (I) as shown above are independently selected from the group consisting of R₁ is hydrogen, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl; R₂ is phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle; R₃ is absent, or if present, is select from the group consisting of hydrogen, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₅ to C₈ heteroaryl, C₅ to C₈ substituted heteroaryl, naphthyl and substituted naphthyl; R₄ is absent, or if present, is select from the group consisting of hydrogen, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₅ to C₈ heteroaryl, C₅ to C₈ substituted heteroaryl, naphthyl and substituted naphthyl; M is O or N or S, however, if M is O or S, one of R₃ or R₄ must be absent; X and Y are both hydrogen, or both methyl, or together represent a carbonyl group.

[030] In a more preferred embodiment of the present invention R₁ is hydrogen, C₁ to C₈ alkyl or C₁ to C₈ substituted alkyl, R₂ is phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle; R₃ is absent, or if present, is hydrogen, C₁ to C₈ alkyl or C₁ to C₈ substituted alkyl; R₄ is C₇ to C₁₂ substituted phenylalkyl, substituted phenyl, C₅ to C₈ substituted heteroaryl or substituted naphthyl; M is O or N or S, however, if M is O or S, one of R₃ or R₄ must be absent; X and Y are both hydrogen, both methyl, or together represent a carbonyl group.

[031] In a more preferred embodiment of the invention, R_1 is hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, alkyl phenyl, substituted phenyl, C_5 to C_8 heteroaryl, C_5 to C_8 substituted heteroaryl, naphthyl or substituted naphthyl; R_2 is substituted phenyl, C_5 to C_8 heteroaryl or C_5 to C_8 substituted heteroaryl; R_3 has one of the following structures;



[032] R_4 is absent;

[033] $M = O$,

[034] both X and Y are hydrogen; and


[035] n is an integer from 0 to 8, preferably 1 to 6, and most preferably, 1 to 4.

[036] The symbol in the above formulas and in formula (II) below:



represents a fragment and covalent linkage between the fragment and the aromatic ring.

[037] An even more preferred embodiment of the invention is a compound, or pharmaceutical acceptable salts or solvates thereof, wherein R_1 is C_1 to C_8 alkyl or C_1 to C_8 substituted alkyl; R_2 is substituted phenyl; R_3 has the following formula (II):



(II)


[038] R_4 is absent

[039] $M = O$,

[040] both X and Y are hydrogen;




[041] and n is an integer from 0 to 8.

[042] A particularly preferred compound which may act as agonist of NR1H4 is shown in formula (II) below. The inventors have been able to demonstrate that the compound according to formula (II) has a low effective concentration at FXR with an EC_{50} of 0.23 μM wherein the EC_{50} reflects the half-maximal effective concentration, and which is higher than the EC_{50} of 0.015 μM for the published FXR agonist GW4064 (B. Goodwin et al., Molecular Cell 6, 517-526, 2000).



(II)

[043] The inventors have also found the compounds according to formulas III, IV and V below to be active as agonist of the NR1H4 human nuclear receptor (see figures for details).



[044] The inventors have identified the compounds as well as the general structure capable of effectively binding FXR.

[045] The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

[046] The term "halogen" refers to the fluoro, chloro, bromo or iodo atoms. There can be one or more halogen, which are the same or different. Preferred halogens are chloro and fluoro.

[047] The term "C₁ to C₈ alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-1-hexyl, 2-methyl-2-hexyl, 2-methyl-3-hexyl, n-octyl and the like.

[048] The term "C₁ to C₈ substituted alkyl" denotes that the above C₁ to C₈ alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C₃ to C₇ cycloalkyl, phenyl, naphthyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C₁ to C₈ alkoxy, C₁ to C₈ acyl, C₁ to C₈ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₈ alkyl)carboxamide, protected N-(C₁ to C₈ alkyl)carboxamide, N,N-di(C₁ to C₈ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

[049] Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyl-oxymethyl, trityloxymethyl, propionyloxymethyl, amino, methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylaminomethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, 4-carboxybutyl, 5-carboxypentyl, 6-carboxyhexyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3-chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1-iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1-aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

[050] The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₁ to C₈ alkoxy, C₁ to C₈ substituted alkoxy, substituted phenoxy, substituted phenyl amine, C₁ to C₈ acyl, C₁ to C₈ substituted acyl, C₁ to C₈ acyloxy, carboxy, protected carboxy, carboxymethyl, protected

carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

[051] Examples of the term "substituted phenyl" include a mono- or di (halo) phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-difluorophenyl, 2,3-difluorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di (hydroxy) phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl)phenyl and the like; a mono or di(alkoxyl)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono-or di(hydroxymethyl)phenyl or (protected hydroxymethyl)-phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonyl-amino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl, 4-(4'-carboxy phenoxy)-phenyl, 4-(4'-protected carboxy phenoxy)-phenyl, 4-(3'-carboxy phenoxy)-phenyl, 4-(3'-protected carboxy phenoxy)-phenyl, 4-(4'-carboxy phenyl amino)-phenyl, 4-(4'-protected carboxy phenyl amino)-phenyl, or 4-(3'-carboxy phenyl amino)-phenyl, 4-(3'-protected carboxy phenyl amino)-phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

[052] The term "C₇ to C₁₂ phenylalkyl" denotes a C₁ to C₆ alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl (n-propyl), 4-phenylhexyl, 3-phenyl (n-amyl), 3-phenyl (sec-butyl) and the like. Preferred C₇ to C₁₂ phenylalkyl groups are the benzyl and the phenylethyl groups.

[053] The term "C₇ to C₁₂ substituted phenylalkyl" denotes a C₇ to C₁₂ phenylalkyl group substituted on the C₁ to C₆ alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₁ to C₈ alkoxy, C₁ to C₈ substituted alkoxy, C₁ to C₈ acyl, C₁ to C₈ substituted acyl, C₁ to C₈ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-(C₁ to C₆ dialkyl)carboxamide, cyano, N-(C₁ to C₆ alkylsulfonyl)amino, thiol, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₁ to C₈ alkoxy, C₁ to C₈ substituted alkoxy, C₁ to C₈ acyl, C₁ to C₈ substituted acyl, C₁ to C₈ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl) carboxamide, protected N-(C₁ to C₆ alkyl) carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C₂ to C₈ alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

[054] Examples of the term "C₇ to C₁₂ substituted phenylalkyl" include groups such as 2-hydroxyphenylmethyl, 3-hydroxyphenylmethyl, 2-methoxyphenylmethyl, 3-methoxyphenylmethyl, 2,6-difluorophenylmethyl, 2,3-difluorophenylmethyl, 2,6-dichlorophenylmethyl, 2,3-dichlorophenylmethyl, 3,5-dichlorophenylmethyl, 2-hydroxyphenylethyl, 3-hydroxyphenylethyl, 2-methoxyphenylethyl, 3-methoxyphenylethyl, 2,6-difluorophenylethyl, 2,3-difluorophenylethyl,

2,6-dichlorophenylethyl, 2,3-dichlorophenylethyl, 3,5-dichlorophenylmethyl 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)- 3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

[055] The term "heterocycle" or "heterocyclic ring" denotes optionally substituted five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazolyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexamethyleneimino and heptamethyleneimino.

[056] The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₈ alkyl, C₁ to C₈ alkoxy, C₁ to C₈ substituted alkoxy, C₁ to C₈ acyl, C₁ to C₈ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino carboxamide, protected carboxamide, N-(C₁ to C₁₂ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle groups.

[057] The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

[058] The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are

the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₈ alkyl, C₁ to C₈ alkoxy, C₁ to C₈ substituted alkoxy, C₁ to C₈ acyl, C₁ to C₈ substituted acyl, C₁ to C₈ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, carboxamide, protected carboxamide, N-(C₁ to C₈ alkyl)carboxamide, protected N-(C₁ to C₈ alkyl)carboxamide, N, N-di(C₁ to C₈ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₈ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino groups.

[059] The term "substituted naphthyl" specifies a naphthyl group substituted with one or more, and preferably one or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₈ alkyl, C₁ to C₈ alkoxy, C₁ to C₈ acyl, C₁ to C₈ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, carboxamide, protected carboxamide, N-(C₁ to C₈ alkyl)carboxamide, protected N-(C₁ to C₈ alkyl)carboxamide, N, N-di(C₁ to C₈ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₈ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

[060] Examples of the term "substituted naphthyl" includes a mono or di (halo) naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di (hydroxy) naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono- or dicarboxynaphthyl or

(protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-carboxynaphthyl or 2, 4-di(-protected carboxy)naphthyl; a mono-or di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di-(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.

[061] As outlined above R_3 and R_4 may be taken together with nitrogen to form a heterocycle or substituted heterocycle of the following kind aziridine, azetidine, pyrrolidine, 3-methylpyrrolidine, 3-aminopyrrolidine, 3-hydroxypyrrolidine, pyrazolidine, imidazolidine, piperidine, 2-methylpiperidine, 4-carboxypiperidine, 4-(carboxymethyl) piperidine, piperazine, morpholine, azepine, tetrahydroisoquinoline.

[062] The term " C_1 to C_8 acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

[063] The term " C_1 to C_8 substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C_1 to C_8 alkoxy, C_1 to C_8 acyl, C_1 to C_8 acyloxy, nitro, C_1 to C_8 alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C_1 to C_8 alkyl)carboxamide, protected N-(C_1 to C_8 alkyl)carboxamide, N,N-di(C_1 to C_8 alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C_1 to C_4 alkylthio or C_1 to C_4

alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

[064] Examples of C₁ to C₈ substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl and the like.

[065] The term "C₁ to C₈ alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C₁ to C₈ substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C₁ to C₈ substituted alkyl.

[066] The term "C₁ to C₈ substituted aminoacyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, monosubstituted amino, protected monosubstituted amino, disubstituted amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₈ alkoxy, C₁ to C₈ acyl, C₁ to C₈ acyloxy, nitro, C₁ to C₈ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₈ alkyl)carboxamide, protected N-(C₁ to C₈ alkyl)carboxamide, N,N-di(C₁ to C₈ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₈ alkylthio or C₁ to C₈ alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

[067] This invention provides a pharmaceutical composition comprising an effective amount of at least one compound according to the invention. Such compositions can be administered by various routes, for example oral, subcutaneous, *via* suppositories intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of the compound for adult human treatment of about 0.01 -5000 mg, preferably about 1-1500 mg per day. The appropriate dose may be administered in a single dose or as divided doses presented at appropriate intervals for example as two, three four or more subdoses per day.

[068] For preparing pharmaceutical compositions containing at least one compound of the invention, inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.

[069] A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

[070] In powders, the carrier is generally a finely divided solid that is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[071] For preparing pharmaceutical compositions in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.

[072] Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.

[073] The pharmaceutical compositions can include the formulation of the active compound(s) with encapsulating material as a carrier providing a capsule in which the active component(s) (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

[074] Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in

solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.







[075] Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.

[076] In particular the invention relates to compounds as described above wherein the compounds are capable of binding the NR1H4 receptor protein or a portion thereof as shown in SEQ ID NO. 1 (Fig. 2A) or a mammalian homologue thereof. The compounds can bind to the NR1H4 receptor protein or a portion thereof in a mixture comprising about 10-200 ng of NR1H4 receptor protein or a portion thereof, preferably the ligand binding domain, 20 mM Tris /HCl at pH 7.9; 60 mM KCl; 5 mM MgCl₂; 160 ng/μl BSA in a total volume of preferably about 25 μl.

[077] A mammalian receptor protein homologue of the protein according to SEQ ID NO. 1 as used herein is a protein that performs substantially the same function as NR1H4 does in humans and shares at least about 40% sequence identity at the amino acid level, preferably about 50 % sequence identity at the amino acid level more preferably about 65 % sequence identity at the amino acid level, even more preferably about 75 % sequence identity at the amino acid level and most preferably over about 85 % sequence identity at the amino acid level.









[078] Table 1 shows the structures of preferred compounds according to the invention. The table further shows their respective EC₅₀ values (EC50 AVG) as established according to results of multiple experiments, as well as their respective average efficacy (% activity relative to CDCA control agonist).

TABLE 1

MOLNAME	MOLECULE STRUCTURE	EC50 AVG	EFFIC AVG
LN0000006772		0.05	100
LN0000006767		0.23	117
LN0000006765		0.43	115
LN0000006734		0.6	85
LN0000006764		0.72	108
LN0000000169		2.6	134

[079] Table 2 shows various known FXR ligands. It is apparent from their structures that the inventors have identified novel compounds that are structurally not related to these known ligands.

TABLE 2

		
Famesol	Famesoic acid	All <i>trans</i> -Retinoic acid
		
TTNPB	LG 268	LG 69
		
Carboxysteroids CDCA	Ethers GW 4064	

[080] As can be seen the compounds of the present invention are structurally unrelated to these known ligands.

[081] The invention in particular concerns a method for prevention or treatment of a NR1H4 receptor protein or NR1H4 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention wherein the prevention or treatment is directly or indirectly accomplished through the binding of a compound according to the invention to the NR1H4 receptor protein or to the NR1H4 receptor protein homologue.

[082] The term mediated herein means that the physiological pathway in which the NR1H4 receptor protein acts is either directly or indirectly involved in the disease or condition to be treated or prevented. In the case where it is indirectly involved it could be that, e.g. modulating the activity of NR1H4 by a compound according to the invention influences a parameter which has a beneficial effect on a disease or a condition. One such example is that modulation of NR1H4 activity leads to decreased levels of serum cholesterol or certain lipoproteins which in turn have a beneficial effect on the prevention and treatment of atherosclerosis. Herein a condition is a physiological or phenotypic state which is desirably altered. Another example would be the treatment of cholestatic conditions in which bile flow from the liver to the gut is impaired which results in a tailback of toxic metabolites to the liver. Cholestasis can be a primary condition where bile flow is directly impaired or a secondary condition where a primary impairment in liver function such as liver cirrhosis results in a secondary cholestasis. Agonists that activate NR1H4 resulting in increased bile acid export from the hepatocyte into the liver canaliculi and subsequent increased bile flow might be used for the treatment of these different types of cholestasis.

[083] In a preferred embodiment of the invention the method for prevention or treatment of a NR1H4 receptor protein mediated disease or condition is applied to a human. This may be male or female.

[084] Listed below are various genes that have been found to be regulated in mammals by binding of an FXR agonist to the FXR receptor.

[085] Genes down-regulated in liver:
Apolipoprotein A1, ApoA1 (NM000039), plasma proteinase inhibitor alpha-1-inhibitor III group 3(m22360), L-glucono-gamma-lactone oxidase (d12754), Peroxisomal enoyl-CoA:hydrotase-3-hydroxyacyl-CoA bifunctional enzyme (k03249) liver fatty acid binding protein (L-FABP, m13501), CYP4A2(m57719,CYP3A23 (x96721), CYP3A1 (x64401);(b), Cholesterol-7-alpha-hydroxylase, CYP7A1 (RefSeq NM000780, XM 005022, XM 044651, XM 044652), Sodium-taurocholate cotransport protein, ntcp (RefSeq NM003049, XM007466), CYP8B1 (NM004391)

[086] Genes up-regulated in liver:

Small heterodimer partner homolog (d86580), Bile salt export pump, bsep (RefSeq NM 003742, XM 003644, XM 033122), Phospholipid transfer protein, PLTP (RefSeq NM 006227, XM 009490, XM 029929, XM 029930), Carnithine palmitoyltransferase II, CPTII (RefSeq NM 000098, XM 001758, XM 038866, XM 038867), Phenylethanolamine-N-methyltransferase, PNMT (RefSeq NM 002686, XM 008597, XM 049837), insulin-induced growth-response protein CL-6 (I13619), elongation factor 2, EF-2 (y07504), mouse cornichon, protein kinase C receptor (u03390), mitochondrial cytochrome c oxidase (m27315), cystathione gamma-lyase (x53460, d17370), cytosolic phosphoenolpyruvate carboxykinase (k03243), histidase (m58308) S-adenosylmethionine synthetase (x60822), lanosterol 14-alpha-demethylase (u17697), G protein-coupled purinoceptor P2U (146865), hepatic squalene synthetase (m95591), ATP-binding cassette transporter, ABCC2 (Q92887), Apolipoprotein CII, APOCII (NM000483), Dehydroepiandrosterone sulfotransferase (XM049895)

[087] Genes regulated in the intestine:

lipase (x61925), pancreatic lipase (d88534), colipase (m58370), pancreatic phospholipase A-2 (d00036), pancreatic amylase (m24962), carboxypeptidase A1 (m23986), carboxypeptidase A2 (m23721), carboxypeptidase B (m23959), pancreatic trypsin I (j00778), pancreatic cationic trypsinogen (m16624), pancreatic trypsinogen II (v01274), elastase I (v01234, I00112), elastase II (I00118, I00124), I-BABP (I22788), intestinal fatty acid binding protein (FABP, k01180), hepatic squalenesynthetase (m95591), protein kinase C receptor (u003390), elongation factor 2, EF-2 (y07504), Small heterodimer partner homolog (d86580)

[088] Pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 µg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, doses is from about 100 µg/kg to about 5 mg/kg body weight, daily.

[089] For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0.1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

[090] By "therapeutically effective amount" is meant a symptom- alleviating or symptom -reducing amount, a cholesterol-reducing amount, an amount that overcomes cholestatic conditions, a protein and/or carbohydrate digestion-blocking amount and/or a de novo cholesterol biosynthesis-blocking amount of a compound according to the invention.

[091] FXR is proposed to be a bile acid sensor. As a result, it modulates both, the synthetic output of bile acids from the liver and their recycling in the intestine, by regulating bile acid binding proteins. In one embodiment of the invention the invention concerns a method for regulating the bile transport system in a mammal, in a preferred embodiment a human, which comprises activating the NR1H4 receptor with a therapeutically effective amount of a compound according to the invention.

[092] Likewise the invention concerns a method of treating in mammal a disease which is affected by cholesterol, triglyceride, bile acid levels or bile flow comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention.

[093] Accordingly, the compounds according to the invention may also be used as a method of prevention or treatment of mammalian atherosclerosis, gallstone disease (cholelithiasis), primary and secondary forms of cholestasis, lipid disorders, obesity or cardiovascular disorders such as coronary heart disease or stroke.

[094] The invention further concerns a method of blocking in a mammal the cholesterol absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention. The invention may also be used to treat obesity in humans.

[095] The Farnesoid X Receptor alpha is a prototypical type 2 nuclear receptor which activates genes upon binding to the promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor. The relevant physiological ligands of NR1H4 are bile acids. The present compounds according to the invention have been demonstrated to have a high binding efficacy as measured as IC50 in the range 400 nM to 1000 nM as well as agonistic and / or

antagonistic properties. Consequently they may be applied to regulate genes that participate in bile acid homeostasis as well as other downstream regulated genes. Examples of physiological functions in which such genes are involved are but are not limited to lipid absorption, cholesterol biosynthesis, cholesterol transport or binding, bile acid synthesis, bile acid transport or binding, proteolysis, amino acid metabolism, glucose biosynthesis, protein translation, electron transport, and hepatic fatty acid metabolism. FXR often functions in vivo as a heterodimer with the Retinoid X Receptor. Published FXR agonists such as the Glaxo SmithKline compound "GW 4064" and published FXR antagonists such as guggulsterone [4,17(20)-pregnadiene-3,16-dione] are known to influence the regulation of various liver genes. Genes found to be regulated by GW 4064 can be found in figure 6. Thus, the invention also concerns a method of modulating a gene whose expression is regulated by the NR1H4 receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention to said mammal.

[096] It is known that the orphan receptor FXR can bind the response element of the shp gene as a heterodimer with RXR (9-cis retinoic acid receptor) and the SHP-protein, in turn, prevents efficient transcription from the cyp7a1 promoter (Lu et al., Mol Cell, 6(3):505-17; Goodwin et al. Mol Cell, 6(3), 717-26, 2000). . Another gene that is repressed via SHP upon FXR activation is the Sodium / Bile Acid Cotransporter gene ntcp, a membrane transport protein which is required for the import of conjugated bile acids into the hepatocyte (Denson et al., Gastroenterology;121(1):218-20, 2001). The gene for the Bile Salt Export Pump, a membrane transporter responsible for the secretion of bile acids into the gall is directly activated by FXR (Ananthanarayanan et al., J Biol Chem, 3;276(31):28857-28865, 2001). Consequently, the invention likewise concerns a method for lowering the expression of cholesterol 7-alpha-hydroxylase and NTCP and increasing expression of BSEP and/ or MDR2 (=multidrug resistance protein 2) in parallel by use of the compounds according to the invention. This is believed to be the ideal profile of an anti-cholestatic compound (Kullack-Ublick, et al., J Hepatol (2000) 32 Suppl 1:3-18). In one embodiment the invention concerns a method for enhancing the expression of the Intestinal Bile Acid Binding Protein (I-BABP) (Grober et al., J Biol Chem, 15;274(42):29749-54, (1999) and/or the activity of the canicular bile salt excretion pump.

[097] The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a NR1H4

receptor protein or NR1H4 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the NR1H4 receptor protein or NR1H4 receptor protein homologue. These pharmaceutical compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

[098] The invention concerns also the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a NR1H4 receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the bile transport system in a mammal preferentially a human by activating the NR1H4 receptor, for regulating levels of cholesterol, triglyceride, bile acids and bile flow in mammals, preferentially humans. The medicament may be used for the treatment of atherosclerosis, gallstone disease (cholelithiasis), cholestasis, lipid disorders, obesity or a cardiovascular disorder.

[099] The further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially a human the cholesterol absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and for modulating a gene whose expression is regulated by the NR1H4 receptor (see details above and figures). The invention further concerns the use of a compound according to the invention for the manufacture of anticancer medicaments. The anticancer effects of such medicaments could be exerted by selective inhibition of cell proliferation and induction of apoptosis of tumor cells in a way similar to described activities for certain bisphosphonates (Alberts DS, et al., Clin Cancer Res 2001 May;7(5):1246-50)

EXAMPLE 1: *in vitro* screening for compounds which influence FXR binding to coactivators.

[100] For screening purposes a fragment of the open reading frame of human FXR alpha (NR1H4 - (Acc. No:AF384555)) encoding aminoacids 187-472 was amplified by standard RT PCR procedures (see figures; SEQ ID NO. 1 and 2). Starting material was total RNA derived from human liver. The resulting cDNA obtained after reverse transcription was subsequently cloned using the Gateway™ recombination technology (Invitrogen, USA) into the expression plasmid pDest15 (Invitrogen, USA). This construct was used to express a recombinant GST-FXR fusion protein in E.coli (BL21 strain). A pDEST 17 derivative clone harboring an additional sequence encoding amino acids 548-878 of human TIF2 (Acc. No: XM_011633 RefSeq) was constructed using Gateway™ recombination technology (Invitrogen, USA) in order to obtain a construct which was used to express recombinant His-tagged TIF2 fragment could be expressed in E. coli. For E. coli expression of both constructs, plasmid DNA was transformed into chemically competent E. coli BL21 (Invitrogen, USA) and cells were grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells were harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins were affinity purified using Glutathion sepharose (Pharmacia) or Ni-NTA Agarose (QIAGEN) according to the instructions of the respective manufacturer. Recombinant proteins were dialyzed against 20 mM Tris/HCL pH 7.9; 60 mM KCl; 5 mM MgCl₂; 1 mM DTT, 0,2 mM PMSF; 10% glycerol. The TIF2 fragment was subsequently biotinylated by addition of 40-120 µl of a Biotinamidocaproate N-Hydroxysuccinimide-ester (Sigma) solution (20 mg/ml in DMSO). Overhead rotating samples were incubated for 2 hours at room temperature. Unincorporated label was then separated using G25 Gel filtration chromatography (Pharmacia Biotech, Sweden). Protein containing fractions from the column were pooled and tested for activity in the assay as described below.

[101] For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the FXR/Tif 2 interaction, the Perkin Elmer LANCE technology was applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology

makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmilä I, Blomberg K and Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3rd Annual Conference of the Society for Biomolecular Screening, Sep., California (1997).

[102] For screening, 20-200 ng of biotinylated Tif 2 fragment and 10-200 ng of GST-FXR fragment were combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0.5-2 µg of Highly fluorescent APC-labelled streptavidin (Perkin Elmer) in the presence of 50 µM of individual compounds to be screened in a total volume of 25 µl of 20 mM Tris /HCl pH 7.9; 60 mM KCl; 5 mM MgCl₂; 160 ng/µl BSA. DMSO content of the samples was kept below 4%. Samples were incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

[103] The LANCE signal was detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results were visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins and labeling reagents giving the most sensitive detection of hits was determined individually by analysis of dose response curves for chenodeoxycholic acid.

TABLE 1: Measurement parameters employed by
a Wallace VICTOR2V™ Multilabel Counter

Number of repeats	1
plate: GREINER FIA-Plate black 384 well med. binding	
Measurement height	3.50 mm
Label technology	TR-F Lance
Emission filter name	D615
Emission filter slot	A1
Emission aperture	Normal
Excitation filter	D340
Delay	50 µs
Window time	400 µs

Cycle	1000 μ s
Light integrator capacitors	1
Light integrator ref. level	95
Flash energy area	High
Flash energy level	223
Flash absorbance measurement	No
Beam	Normal
Label technology	TR-F Lance
Emission filter name	D665
Emission filter slot	A8
Emission aperture	Normal
Excitation filter	D340
Delay	50 μ s
Window time	400 μ s
Cycle	1000 μ s
Light integrator capacitors	1
Light integrator ref. level	95
Flash energy area	High
Flash energy level	223
Flash absorbance measurement	No
Beam	Normal

EXAMPLE 2: Experimental procedure for the preparation of the compounds according to the invention.

[104] The following steps describe the experimental procedure for the preparation of the compounds according to the invention. The synthesis scheme is shown in Fig. 1.

Step 1: Synthesis of Dichlorobenzaldehyde oxime (compound 3).

[105] A solution of 2,6-dichlorobenzaldehyde (compound 2) (0.14mole) in ethanol (200mL) was added to a solution of hydroxylamine hydrochloride (0.16mole) and sodium hydroxide (0.16mole) in water (100ml). The resulting mixture was stirred at 90°C for 24 hours. The volume of the reaction mixture was reduced in vacuo by ~30 mL, which induced a precipitate. The white solids were collected by filtration and washed with water (2x100 mL) to yield (96%) of dichlorobenzaldehyde oxime (compound 3).

Step 2: Synthesis of 3-(2,6-dichlorophenyl)-4-carbomethoxy-5-isopropyl-isoxazole (compound 5).

[106] N-chlorosuccinimide (0.07mole) was added at room temperature to a solution of 2,6-dichlorobenzaldehyde oxime (compound 3) (0.07mole) in DMF (150mL). The reaction was slightly exothermic and the reaction mixture turned into dark yellow color. The reaction mixture was stirred for an additional one hour, and then the contents were poured into water (200mL) and extracted with diethyl ether (300mL). The organic layer was washed with water (3x100mL) and brine (50mL), dried (Na_2SO_4) and concentrated to obtain 2,6-dichlorophenylhydroxamic chloride (94%). A stirred solution of methyl isobutyryl acetate (compound 4) (15.6mmol) in tetrahydrofuran (15mL) was treated with a solution of sodium methoxide (31.5mL, 0.5M in methanol) followed by a solution of 2,6-dichlorophenylhydroxamic chloride (15.6 mmol) in tetrahydrofuran (5 mL). After stirring at room temperature for 16 hours the solvent was removed in vacuo. The resulting residue was partitioned with diethyl ether (100 mL) and water (100 mL). The ether layer was washed with brine (50 mL), dried (Na_2SO_4), and concentrated to obtain a

residue which was purified by flash column chromatography on silica gel using 10% ethyl acetate in hexane as mobile phase to yield 3.1g(62%) of 3-(2,6-dichlorophenyl)-4-carbomethoxy-5-isopropyl-isoxazole (compound 5).

Step 3: Reduction.

[107] A solution of 3-(2,6-dichlorophenyl)-4-carbomethoxy-5-isopropyl-isoxazole (compound 5) (27 mmol) in tetrahydrofuran (60 mL) was cooled to 0°C under a nitrogen atmosphere. A solution of diisobutylaluminum hydride (38 ml 2.1 eq, 1.5 M in toluene) was added dropwise. The reaction mixture was allowed to warm up to room temperature and was stirred for an additional 16 hours. The reaction mixture was cooled to 0°C and quenched with methanol (2 mL). When water (20 mL) was added dropwise a gelatinous precipitate was obtained. Sodium hydroxide (30 mL, 2N) was then added and the material was filtered through celite. The filtrate was extracted with ethyl acetate, washed with water and saturated sodium chloride solution, dried (Na₂SO₄), and concentrated to obtain the alcohol (compound 6).

Step 4: Mitsunobu Reaction.

[108] To a solution of phenol (compound 7) (0.6 mmol), isoxazole (compound 6) (0.6mmol) and triphenylphosphine (0.6mmol) in dichloromethane (10mL), diisopropyl azodicarboxylate((0.6mmol) was added dropwise. A brief exotherm was observed and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated to a residue and was purified by flash column chromatography using 20% ethyl acetate in hexane as eluant to obtain 8 in 85% yield.

Step 5: Ester Hydrolysis.

[109] Lithium hydroxide (0.8 mmol, 1M in water) was added to a solution of ester (compound 8) (0.2 mmol) in THF (5 mL). The reaction mixture was stirred vigorously at room temperature for 24 hours. THF was removed *in vacuo* and the reaction mixture was extracted with ethyl acetate, dried (Na₂SO₄), and concentrated to obtain an oil which was purified by flash column chromatography to form compound 8.

[110] All of the final products were analyzed using an Evaporative Light Scattering Detector (ELSD) detection to determine purity. One skilled in the art will be able to arrive at the compounds claimed herein making use of the above protocol.

[111] A compound according to the invention (experiments shown were done with MOLSTRUCTURE LN 6734; see Table 1 for structural formula) can mediate transactivation of FXR-mediated transcription in a HEK293 reporter cell line. Stable HEK293FXR reporter cell lines were generated by stably transfecting with the pTRexDest30 (Invitrogen) derivatives pTRexDest30-hFXR, pTRexDest30-hRXR and the pGL2promoter (Promega) derivative, pGL2promoter-FXRRE. The full length human FXR (accession U68233) and the full length human RXR α (accession P19793) were cloned into the pTRexDest30 applying the manufacturer protocols for the GatewayTM system (Invitrogen).

[112] The FXR response elements were (upper case and underlined)
5' - cccaGGGTGAaTAACCTcggggctctgtccctccaatcccaGGGTGAaTAACCTcggg 3' (SEQ ID NO. 5) was created from the human IBAB-P promoter (Grober et al 1999, JBC 274, pp. 29749-29754) and integrated into the reporter plasmid pGL2promoter (Promega) according to standard methods known to those skilled in the art. A stable clone was selected and seeded at a density of 1×10^4 cells per well in 96 well plates. Luciferase reporter activity were determined in triplicates from extracts of cells after incubating cells in culture medium (DMEM [Gibco-BRL] + 10% FCS [PAA laboratories]) for 16 hours (5% CO₂, 37°C) containing 0,5% DMSO (control) or 0,5% DMSO with increasing concentrations of LN6691 (Fig. 3).
The EC50 value derived in this experiment is 1.3 μ M and the relative efficacy compared to the GW4064 as a control compound is about 110% (Fig 3).

[113] Preferred examples of compounds of the invention are shown below in Table 4, together with their dose response curves done for LN6991 and GW4064, CDCA and LN12996 as control compounds are shown in Fig. 3.

TABLE 4


μM	CDCA	LN0000000169	LN00000006734	TR 0800012996	GW 4064
50	6310.0	13375.7	13309.5	5626.0	2159.3
10	3300.7	6829.3	8523.5	8286.0	4030.3
2	1784.0	5775.7	6330.5	4341.0	6084.0
1	1597.7	4600.0	5360.5	3118.0	7440.7
0.4	1421.8	2754.0	2991.5	2491.0	8416.3
0.08	1256.5	1630.0	2153.0	1896.0	6704.7
0.016	1294.3	1333.0	2077.0	2132.0	3319.0
0	1257.7	1396.3	1748.8	1971.1	1274.1

All data are measured in triplicates
max standard deviation +/- 20%

[114] While the salient features of the invention have been illustrated and described with respect to particular embodiments, it should be readily apparent that modifications can be made within the spirit and scope of the invention, and it is, therefore, not desired to limit the invention to the exact details shown and described.

What is claimed is:

1. A compound including or a pharmaceutical acceptable salt or solvate thereof,



(I)

wherein:

R_1 is hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, naphthyl or substituted naphthyl;

R_2 is phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, heterocycle, substituted heterocycle, naphthyl or substituted naphthyl;

R_3 is absent, or if present, is hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, biphenyl, substituted biphenyl, biphenyl ether, substituted biphenyl ether, biphenyl amine, substituted biphenyl amine, naphthyl or substituted naphthyl;

R_4 is absent, or if present, is hydrogen, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, biphenyl, substituted biphenyl, biphenyl ether, substituted biphenyl ether, biphenyl amine, substituted biphenyl amine, naphthyl or substituted naphthyl;

R_3 and R_4 may be taken together with nitrogen to form a heterocycle or substituted heterocycle;

M is O or N or S; and if M is O or S, one of R_3 or R_4 must be absent; and


X and Y are both hydrogen or both methyl, or together represent a carbonyl group.

2. The compound of claim 1, wherein:

R₁ is hydrogen, C₁ to C₈ alkyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl;

R₂ is substituted phenyl, C₅ to C₆ heteroaryl, or C₅ to C₆ substituted heteroaryl;

R₃ is a formula having the following formula (II),



(II);

R₄ is absent;

M is O; and


X and Y are both hydrogen.

3. A compound of claim 2, wherein:

R₁ is hydrogen, C₁ to C₈ alkyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl;

R₂ is substituted phenyl, C₅ to C₆ heteroaryl, or C₅ to C₆ substituted heteroaryl;

R₃ is a formula having the following formula (II),




(II);

R₄ is hydrogen;


M = N; and

X and Y are both hydrogen.


4. The compound according to any of the claims 1 to 3 wherein the compound is




5. The compound according to any of the claims 1 to 3, wherein the compound is




6. The compound according to any of the claims 1 to 3, wherein the compound is




7. The compound according to any of the claims 1 to 3, wherein the compound is



8. The compound according to any of the claims 1 to 3, wherein the compound is



9. The compound according to any of the claims 1 to 3, wherein the compound is



10. A compound according to any of claims 1 to 9 for use as a medicament.
11. A compound according to any of claims 1 to 9 wherein said compound is capable of binding the human NR1H4 receptor protein or a portion thereof or a mammalian homologue thereof according to SEQ ID NO. 1.

12. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for the treatment of a NR1H4 receptor mediated or treatable disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to any of claims 1 to 9.
13. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for regulating bile flow or the bile acid transport system in a mammal by activating or repressing the NR1H4 receptor with a therapeutically effective amount of a compound according to any of claims 1 to 9.
14. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for regulating blood levels of cholesterol, lipoproteins, phospholipids, triglycerides, or bile acids and/or bile flow or bile levels of cholesterol, phospholipids or bile acids in a mammal in need of such treatment with a therapeutically effective amount of a compound according to any of claims 1 to 9.
15. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for treating cholestatic conditions such as primary biliary cirrhosis (PBC), progressive familial cholestasis (PFIC), estrogen or drug induced cholestasis, any form of extrahepatic cholestasis, or secondary forms of cholestasis, atherosclerosis, gallstone disease (cholelithiasis), lipid disorders, obesity or a cardiovascular or metabolic disorder in a mammal in need of such treatment with a therapeutically effective amount of a compound according to any of claims 1 to 9.
16. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for treating in a mammal malign proliferative diseases such as cancer which can be treated or cured by inducing apoptosis in the affected cells

or tissues comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9.

17. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for treating in a mammal conditions of drug resistance that arise during drug treatment of disorders such as cancer or infectious diseases, or during continuous administration of contraceptive drugs comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9.
18. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament capable of blocking in a mammal cholesterol absorption or capable of reducing the bile acid reabsorption in the intestine in a mammal in need of such treatment comprising administration of a therapeutically effective amount of a compound according to any of claims 1 to 9.
19. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for regulating the expression of NR1H4 responsive genes such as cholesterol-7-alpha hydroxylase (cyp7a1), sterol-12-alpha hydroxylase (cyp8b1), small heterodimer partner (shp), phospholipid transfer protein (pltp), bile salt export pump (bsep), sodium-taurocholate co-transporter (ntcp), organic anion transport proteins 1 and 2 (oatp1 and -2), canalicular multidrug resistance protein 2 (mdr2) or other genes that are members of the cytochrom P450 family or members of the ABC-transporter family or members of the MDR class III multidrug resistance proteins or members of the MRP multidrug resistance protein family or members of the nuclear receptor gene family through activating or repressing the NR1H4 receptor in a mammal in need of such treatment by a therapeutically effective amount of a compound according to any of claims 1 to 9.

20. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for modulating the expression of the intestinal bile acid binding protein (IBABP) in intestinal mucosa cells and/or cholangiocytes by the NR1H4 receptor in a mammal in need of such treatment by a therapeutically effective amount of a compound according to any of claims 1 to 9.
21. Use according to any of claims 12 to 20 wherein the mammal is a human.
22. A method for prevention or treatment of a disease or condition which is mediated or can be addressed by the NR1H4 receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to any of claims 1 to 9.
23. A method for regulating bile flow or the bile acid transport system in a mammal which comprises activating or repressing the NR1H4 receptor with a therapeutically effective amount of a compound according to any of claims 1 to 9.
24. A method of treating in a mammal a disease or condition which is affected by impaired blood levels of cholesterol, lipoproteins, phospholipids, triglycerides, or bile acids and/or impaired bile flow or impaired bile levels of cholesterol, phospholipids or bile acids comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9.
25. A method of treating in a mammal cholestatic conditions such as primary biliary cirrhosis (PBC), progressive familial cholestasis (PFIC), estrogen or drug induced cholestasis, any form of extrahepatic cholestasis, or secondary forms of cholestasis, atherosclerosis, gallstone disease, lipid disorders, obesity or a

cardiovascular or metabolic disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9.

26. A method for treating in a mammal malignant proliferative diseases such as cancer which can be treated by inducing apoptosis in the affected cells or tissues comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9
27. A method for treating in a mammal conditions of drug resistance that arise during drug treatment of disorders such as cancer or infectious diseases, or during continuous administration of contraceptive drugs comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9.
28. A method of blocking in a mammal the cholesterol absorption or bile acid re-absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 9.
29. A method for regulating the expression of NR1H4 responsive genes such as cholesterol-7- α hydroxylase (cyp7a1), sterol-12- α hydroxylase (cyp8b1), small heterodimer partner (shp), phospholipid transfer protein (pltp), bile salt export pump (bsep), sodium-taurocholate co-transporter (ntcp), organic anion transport proteins 1 and 2 (oatp1 and -2), canalicular multidrug resistance protein 2 (mdr2) or other genes that are members of the cytochrom P450 family or members of the ABC-transporter family or members of the MDR class III multidrug resistance proteins or members of the MRP multidrug resistance protein family or members of the nuclear receptor gene family by the NR1H4

receptor in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 9.

30. A method for modulating the expression of the intestinal bile acid binding protein (IBABP) in intestinal mucosa cells and/or cholangiocytes by the NR1H4 receptor in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 9.
31. A method according to any of claims 22 to 30 where the mammal is a human.

FIG. 1




Fig. 2 A**SEQ ID NO. 1**

MGSKMNLIEH	SHLPTTDEFS	FSENLFQVLT	EQVAGPLGQN	LEVEPYSQYS	NVQFPQVQPO	60
ISSSSYYSNL	GFYPQQPEEW	YSPGIYELRR	MPAETLYQGE	TEVAEMPVTK	KPRMGASAGR	120
IKGDELVCVC	GDRASGYHYN	ALTCEGCKGF	FRRSITKNAV	YKCKNGGNCV	MDMYMRRKCQ	180
ECRLRKCKEM	GMLAECMYTG	LLTEIQCKSK	RLRKQNVKQHA	DQTVNEDSEG	RDLRQVTSTT	240
KSCREKTELT	PDQQTLLHFI	MDSYNKQRMF	QEITNKILKE	EFSAEENFLI	LTEMATNHVQ	300
VLVEFTKKLP	GFQTLDDHEDQ	IALLKGSAGE	AMFLRSAEIF	NKKLPSGHSD	LLEERIRNSG	360
ISDEYITPMF	SFYKSIGELK	MTQEEYALLT	AIVILSPDRQ	YIKDREAVEK	LQEPLLDVLQ	420
KLCKIHQPEN	PQHFACLLGR	LTELRTFNHH	HAEMLSWRV	NDHKFTPLLC	EIWDVQ	476

FIG 2B

SEQ ID NO. 2

atgggatcaa	aaatgaatct	cattgaacat	tcccatttac	ctaccacaga	tgaattttct	60
ttttctgaaa	atttatttgg	tgttttaaca	gaacaagtgg	caggtcctct	gggacagaac	120
ctggaagtgg	aaccatactc	gcaatacagc	aatgttcagt	ttccccaagt	tcaaccacag	180
atttctctgt	catcctatta	ttccaacctg	ggtttctacc	cccagcagcc	tgaagagtgg	240
tactctcctg	gaatatatga	actcaggcgt	atgccagctg	agactctcta	ccagggagaa	300
actgaggtag	cagagatgcc	tgtaacaaag	aagccccgca	tgggcgcgtc	agcagggagg	360
atcaaagggg	atgagctgtg	tgttgtttgt	ggagacagag	cctctggata	ccactataat	420
gcactgacct	gtgaggggtg	taaaggtttc	ttcaggagaa	gcattaccaa	aaacgctgtg	480
tacaagtgtg	aaaacggggg	caactgtgtg	atggatatgt	acatgcgaag	aaagtgtcaa	540
gagtgtcgac	taaggaaatg	caaagagatg	ggaatgttgg	ctgaatgtat	gtatacaggc	600
ttgttaactg	aaattcagtg	taaatctaag	cgactgagaa	aaaatgtgaa	gcagcatgca	660
gatcagaccg	tgaatgaaga	cagtgaagggt	cgtgacttgc	gacaagtgc	ctcgacaaca	720
aaatcatgca	gggagaaaac	tgaactcacc	ccagatcaac	agactcttct	acattttatt	780
atggattcat	ataacaaaca	gaggatgcct	caggaaataa	caaataaaat	tttaaaagaa	840
gaattcagtg	cagaagaaaa	ttttctcatt	ttgacggaaa	tggcaaccaa	tcattgtacag	900
gttctttag	aattcacaaa	aaagctacca	ggatttcaga	ctttggacca	tgaagaccag	960
attgctttgc	tgaagggttc	tgcggttgaa	gctatgttcc	ttcgttcagc	tgagattttc	1020
aataagaaaac	ttccgtctgg	gcattctgac	ctattggaag	aaagaattcg	aaatagtggg	1080
atctctgatg	aatatataac	acctatgttt	agtttttata	aaagtattgg	ggaactgaaa	1140
atgactcaag	aggagtatgc	tctgcttaca	gcaattgtta	tcctgtctcc	agatagacaa	1200
tacataaagg	atagagaggg	agtagagaag	cttcaggagc	cacttcttga	tgtgctacaa	1260
aaagtgtgta	agattcacca	gcctgaaaat	cctcaacact	ttgctgtgtc	cctgggtcgc	1320
ctgactgaat	tacggacatt	caatcatcac	cacgctgaga	tgctgatgtc	atggagagta	1380
aacgaccaca	agttttaccc	acttctctgt	gaaatctggg	acgtgcagtg	a	1431

FIG. 2C

SEQ ID NO. 3

MLVKPLPDSE	EEGHDNQEAH	QKYETMQCFA	VSQPKSIKEE	GEDLQSCLIC	VARRVPMKER	60
PVLPSSESFT	TRQDLQGGKIT	SLDTSTMRAA	MKPGWEDLVR	RCIQKFHAQH	EGESVSYAKR	120
HHHEVLROGL	AFSQIYRFSL	SDGTLVAAQT	KSKLIRSQTT	NEPQLVISLH	MLHREQNVCV	180
MNPDLTGQTM	GKPLNPISSN	SPAHQALCSG	NPGQDMTLSS	NINFPINGPK	EQMGMPMGRF	240
GGSGGMNHVS	GMQATTPOGS	NYALKMNSPS	QSSPGMNPQG	PTSMLSPRHR	MSPGVAGSPR	300
IPPSQFSPAG	SLHSPVGVCS	STGNSHSYTN	SSLNALQALS	EGHGVSLGSS	LASPDLMGN	360
LQNSPVNMNP	PPLSKMGSLD	SKDCFGLYGE	PSEGTGQAE	SSCHPGEQKE	TNDPNLPPAV	420
SSERADGQSR	LHDSKGQTKL	LQLLTKSDQ	MEPSPLASSL	SDTNKDSTGS	LPGSGSTHGT	480
SLKEKKHILH	RLQDSSSPV	DLAKLTAEAT	GKDLSQESSS	TAPGSEVTIK	QEPVSPKKKE	540
NALLRYLLDK	DDTKDIGLPE	ITPKLERLDS	KTDPAANTKL	IAMKTEKEEM	SFEPGDQPGS	600
ELDNLEEILD	DLQNSQLPQL	FPDTRPGAPA	GSVDKQAIIN	DLMLTAENS	PVTPVGAQKT	660
ALRISQSTFN	NPRPGQLGRL	LPNQNLPLDI	TLQSPGTAGP	FPPIRNSSPY	SVIPQPGMMG	720
NQGMIGNQGN	LGNSSTGMIG	NSASRPTMPS	GEWAPQSSAV	RVTCAATTSA	MNRPVQGGMI	780
RNPAASIPMR	PSSQPGQRT	LQSQVMNIGP	SELEMMNGGP	QYSQQQAPPN	QTAPWPESIL	840
PIDQASFASQ	NRQPFSSPD	DLLCPHPAAE	SPSDEGALLD	QLYLALRNFD	GLEEIDRALG	900
IPELVSSQSA	VDPEQFSSQD	SNIMLEQKAP	VFPQQYASQA	QMAQGSYSYM	QDPNFHTMGQ	960
RPSYATLRMQ	PRPGLRPTGL	VONQPNQLRL	QLQHRLQAQQ	NRQPLMNQIS	NVSNVNLTLR	1020
PGVPTQAPIN	AQMLAQRRRE	ILNQHLRQRQ	MHQQQQVQQR	TLMMRGQGLN	MTFSMVAPSG	1080
MPATMSNPRI	PQANAQQFPF	PPNYGISQQP	DPGFTGATTG	QSPLMSPRMA	HTQSPMMQQS	1140
QANPAYQAPS	DINGWAQGNM	GGNSMFSQQS	PPHFGQANT	SMYSNNMNIN	VSMATNTGGM	1200
SSMNQMTGQI	SMTSVTSVPT	SGLSSMGPEQ	VNDPALRGGN	LFPNQLPGMD	MIKQEGDTTR	1260
KYC						1263

FIG. 2D

SEQ ID NO. 4

```
1  ggccggccga  gcttcggcta  cagcttcggc  ggccgaagtc  agccggcagc  gcagccggca
61  cctgacggcg  tgaccgaccc  gagccgattt  ctcttggtat  tggctacaca  cttatagatc
121  ttctgactgc  ttacaggcca  cagttgctga  tatgtgttca  agatgagtgg  gatgggagaa
181  aatacctctg  acccctccag  ggccagagaca  agaaagcgca  aggaatgtcc  tgaccaactt
241  ggacccagcc  ccaaaaggaa  cactgaaaaa  cgtaatcgtg  aacaggaaaa  taaatatata
301  gaagaacttg  cagagttgat  ttttgcaaat  tttaatgata  tagacaactt  taacttcaaa
361  cctgacaaat  gtgcaatctt  aaaagaaact  gtgaagcaaa  ttcgtcagat  caaagaacaa
421  gagaagcagc  cagctgccta  catagatgaa  gtgcagaagt  cagatgtatc  ctctacaggg
481  cagggtgtca  tcgacaagga  tgcgtcgggg  cctatgatgc  ttgaggccct  tgatgggttc
541  ttctttgtag  tgaacctgga  aggcaacgtt  gtgtttgtgt  cagagaatgt  gacacagtat
601  ctaagggtata  accaagaaga  gctgatgaac  aaaagtgtat  atagcatctt  gcatgttggg
661  gaccacacgg  aatttgtcaa  aaacctgctg  ccaaagtcta  taggtaaatg  ggggatcttg
721  gtctggcgaa  cctccgaggg  ggaacagcca  taccttcaat  tgcggatgc  tggtaaaacc
781  ttacctgat  tcagaagagg  agggctcatga  taaccaggaa  gctcatcaga  aatatgaaac
841  tatgcagtgc  ttctgctgtc  ctcaaccaa  gtccatcaaa  gaagaaggag  aagatttgca
901  gctctgcttg  atttgcgtgg  caagaagagt  tcccatgaag  gaaagaccag  ttcttccctc
961  atcagaaggt  ttactacttc  gccaggatct  ccaaggcaag  atcacgtctc  tggataccag
1021  caccatgaga  gcagccatga  aaccaggctg  ggaggacctg  gtaagaaggt  gtattcagaa
1081  gttccatgct  cagcatgaag  gagaatctgt  gtccatgct  aagaggcatc  atcatgaagt
1141  actgagacaa  ggattggcat  tcagtcaaat  ctatcgtttt  tccttgtctg  atggcactct
1201  tgttgctgca  caaacgaaga  gcaaacatcat  ccgttctcag  actactaatg  aacctcaact

1261  tgtaatatct  ttacatatgc  ttacacagaga  gcagaatgtg  tgtgtgatga  atccggatct
1321  gactggacaa  acgatgggga  agccactgaa  tccaattagc  tctaacagcc  ctgcccatca
1381  ggccctgtgc  agtgggaacc  caggctcagga  catgaccctc  agtagcaata  taaattttcc
1441  cataaatggc  ccaaaggaa  aaatgggcat  gccatggggc  aggtttgggtg  gtctcggggg
1501  aatgaacat  gtgtcaggca  tgcaagcaac  cactcctcag  ggtagtaact  atgcactcaa
1561  aatgaacagc  ccctcacaaa  gcagccctgg  catgaatcca  ggacagccca  cctccatgct
1621  ttaccacagg  catcgcatga  gccctggagt  ggctggcagc  cctcgaatcc  caccagtgca
1681  gttttccct  gcaggaaagt  tgcattcccc  tgtgggagt  tgcagcagca  caggaaatag
1741  ccatagttat  accaacagct  ccctcaatgc  acttcaggcc  ctccagcagg  ggcacggggg
1801  ctcattaggg  tcatcgttgg  cttcaccaga  cctaaaaatg  ggcaatttgc  aaaactcccc
1861  agttaatatg  aatcctcccc  cactcagcaa  gatgggaagc  ttggactcaa  aagactgttt
1921  tggactatct  ggggagccct  ctgaaggtac  aactggacaa  gcagagagca  gctgccatcc
1981  tggagagcaa  aaggaacaaa  atgaccccaa  cctgcccccg  gccgtgagca  gtgagagagc
2041  tgacggcgag  agcagactgc  atgacagcaa  agggcagacc  aaactcctgc  agctgctgac
2101  caccaaatct  gatcagatgg  agccctcgcc  cttagccagc  tctttgtcgg  atacaaacaa
2161  agactccaca  ggtagcttgc  ctggttcttg  gtctacacat  ggaacctcgc  tcaaggagaa
2221  gcataaaatt  ttgcacagac  tcttgacgga  cagcagttcc  cctgtggact  tggccaagtt
2281  aacagcagaa  gccacaggca  aagacctgag  ccaggagtcc  agcagcacag  ctccctggatc
2341  agaagtgcct  attaaacaag  agccggtgag  ccccaagaag  aaagagaatg  cactacttcg
2401  ctatttgcta  gataaagatg  atactaaaga  tattggttta  ccagaaataa  cccccaaact
2461  tgagagactg  gacagtaaga  cagatcctgc  cagtaacaca  aaattaatag  caatgaaac
2521  tgagaaggag  gagatgagct  ttgagcctgg  tgaccagcct  ggcagtgagc  tggacaactt
2581  ggaggagatt  ttgagtgatt  tgcagaatag  tcaattacca  cagcttttcc  cagacacgag
2641  gccaggcgcc  cctgctggat  cagttgacaa  gcaagccatc  atcaatgacc  tcatgcaact
2701  cacagctgaa  aacagccctg  tcacacctgt  tggagcccag  aaaacagcac  tgcgaatttc
2761  acagagcact  ttaataaacc  cagcaccagg  gcaactgggc  aggttattgc  caaaccagaa
2821  ttaccactt  gacatcacat  tgcaaacccc  aactggtgct  ggacctttcc  caccaatcag
2881  aaacagtagt  ccctactcag  tgatacctca  gccaggaatg  atgggtaatc  aagggatgat
2941  agaaaaccaa  ggaatttag  ggaacagtag  cacaggaatg  attggttaaca  gtgcttctcg
3001  gcctactatg  ccatctggag  aatgggcacc  gcagagtctg  gctgtgagag  tcacctgtgc
3061  tgctaccacc  agtgccatga  accggccagt  ccaaggaggt  atgattcgga  acccagcagc
3121  cagcatcccc  atgaggccca  gcagccagcc  tggccaaaga  cagacgcttc  agtctcaggt
3181  catgaatata  gggccatctg  aattagagat  gaacatgggg  ggacctcagt  atagccaaca
3241  acaagctcct  ccaaatcaga  ctgccccatg  gcctgaaagc  atcctgccta  tagaccaggg
3301  gtcttttgcc  agccaaaaca  ggcaagccatt  tggcagttct  ccagatgact  tgctatgtcc
3361  acatcctgca  gctgagcttc  cgagtgtatg  gggagctctc  ctggaccagc  tgtatctggc
3421  ctctgggaat  ttgatgggcc  tggaggagat  tgatagagcc  ttaggaatac  ccgaactggt
3481  cagccagagc  caagcagtag  atccagaaca  gttctcaagt  caggattcca  acatcatgct
3541  ggagcagaag  gcgcccgttt  tcccacagca  gtatgcactc  caggcacaaa  tggcccaggg
3601  tagctattct  cccatgcaag  atccaaactt  tcacaccatg  ggacagcgcc  ctagtattgc
3661  cacactccgt  atgcagccca  gaccgggcct  caggccccag  ggcctagtgc  agaaccagcc
3721  aaatcaacta  agacttcaac  ttcagcatcg  cctccaagca  cagcagaatc  gccagccact
```


3781 tatgaatcaa atcagcaatg tttccaatgt gaacttgact ctgaggcctg gagtaccaa
3841 acaggcacct attaatgcac agatgctggc ccagagacag agggaaatcc tgaaccagca
3901 tcttcgacag agacaaatgc atcagcaaca gcaagtccag caacgaactt tgatgatgag
3961 aggacaaggg ttgaatatga caccaagcat ggtggctcct agtggtatgc cagcaactat
4021 gagcaaccct cggattcccc aggc aaatgc acagcagttt ccatttcctc caaactacgg
4081 aataagtcag caacctgatc cagggtttac tggggctacg actcccaga gccacttat
4141 gtcaccccgga atggcacata cacagagtcc catgatgcaa cagtctcagg ccaaccacgc
4201 ctatcaggcc cccctccgaca taaatggatg ggcgcagggg aacatgggag gaaacagcat

4261 gttttcccag cagtccccac cacactttgg gcagcaagca aacaccagca tgtacagtaa
4321 caacatgaac atcaatgtgt ccatggcgac caacacaggt ggcatgagca gcatgaacca
4381 gatgacagga cagatcagca tgacctcagt gacctccgtg cctacgtcag ggctgtcctc
4441 catgggtccc gagcagggtta atgatcctgc tctgagggga ggcaacctgt tcccaaacca
4501 gctgccttga atggatatga ttaagcagga gggagacaca acacggaaat attgctgaca
4561 ctgctgaagc cagttgtctt ttcagctgac cgggctcact tgctcaaaac acttccagtc
4621 tggagagctg tgtctatttg tttcaaccca actgacctgc cagccgggtc tgcctagagca
4681 gacaggcctg gccctgggtc ccagggtggc gtccactcgg ctgtggcagg agggagtggc
4741 tcttctcttg acagtctgaa gctcgcaccc agacagtgcg tcagtctgtt cactgcattc
4801 accttagtgc aacttagatc tctcctgcaa aagtaaatgt tgacaggcaa atttcatacc
4861 catgtcagat tgaatgtatt taaatgtatg tatttaagga gaacctgct cttgttctgt
4921 tctgttctgg ttcacagcac tgggttcttg ctttgttttc cctggctaac agtctagtgc
4981 aaaagattaa gattttatct gggggaaaga aaagaatttt ttaaaaaatt aaactaaga
5041 tgttttaagc taaagcctga atttgggatg gaagcaggac agacaccgtg gacagcgctg
5101 tatttacaga cacaccagtg gcgtgaagac caacaaagtc acagtctgat ctctagaaag
5161 ctctaaagac catgttggaa agagtctcca gttactgaac agatgaaaag gaggcctgtga
5221 gagggtgtgt aacattagca aatatttttt ccttgttttt tctttgttaa aaccaaactg
5281 gttcacctga atcatgaatt gagaagaaat aattttcatt tctaaattaa gtccctttta
5341 gtttgatcag acagcttgaa tcagcatctc ttcttccttg tcagcctgac tcttcccttc
5401 ccctctctca tccccatac tccctatttt cattcctttt ttaaaaaata atataagcta
5461 cagaaaccag gtaagccctt tatttcctta aatgttttgc cagccactta ccaattgcta
5521 agtattgaat ttcagaaaaa aaaaatgcat ttactggcaa ggagaagagc aaagttaagg
5581 cttgatacca atcgagctaa ggatacctgc tttggaagca tgtttattct gttcccacgc
5641 aactctggcc tccaaaatgg gagaaaacgc cagtgtgttt aaattgatag cagatatcac
5701 gacagattta acctctgcca tgtgtttttt attttgtttt ttagcagtgc tgactaagcc
5761 gaagttttgt aaggtacata aaatccaatt tatatgtaaa caagcaataa ttttaagttga
5821 gaaacttatgt gttttaattg tataattttt gtgaggata catattgtgg aattgactca
5881 aaaaatgaggt acttcagtat taaattagat atcttcatag caatgtctcc taaaggtgtt
5941 ttgtaaaagga tatcaatgcc ttgattagac ctaatttgta gacttaagac tttttatttt
6001 ctaaaccttg tgattctgct tataagtcac ttatctaata tatatgatat gcagccgctg
6061 taggaaccaa ttcttgatgt ttatatgttt atattctttc ttaatgaacc ttagaaagac
6121 tacatgttac taagcaggcc acttttatgg ttgttttt.

FIG. 3




Fig. 4

μM	CDCA	LN169	LN6734	LN12996	GW 4064
50	6310,0	13375,7	13309,5	5626,0	2159,3
10	3300,7	6829,3	8523,5	8286,0	4030,3
2	1784,0	5775,7	6330,5	4341,0	6084,0
1	1597,7	4600,0	5360,5	3118,0	7440,7
0,4	1421,8	2754,0	2991,5	2491,0	8416,3
0,08	1256,5	1630,0	2153,0	1896,0	6704,7
0,016	1294,3	1333,0	2077,0	2132,0	3319,0
0	1257,7	1396,3	1748,8	1971,1	1274,1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/25437

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 31/42; C07D 261/08

US CL :514/378; 548/247, 249

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/378; 548/247, 249

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chem. Astr., Vol. 121, No. 23, 05 December 1994 (Columbus OH, USA), page 39, column 1, the abstract No. 271343d, LIM, JUNG KI et al. 'Analgesic, anti-inflammatory and antiviral effects of melandrin derivatives.' Yakhak Hoechi. 1994, 38(3), 345-50 (Korean).	1-9

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 18 SEPTEMBER 2002	Date of mailing of the international search report 17 DEC 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Laurel L. Stockton</i> LAUREL L. STOCKTON Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/25437

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 10-31
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.